SII seeks market authorisation from DCGI for India’s first qHPV vaccine against cervical cancer

The Serum Institute of India (SII) has applied to the country’s drug regulator seeking market authorisation to manufacture indigenously developed India’s first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer, official sources said recently.

The firm has applied for market authorisation after completing the phase-II/III clinical trial with support of the Department of Biotechnology (DBT) to ensure its early availability in the country, they said.

In the application to the Drugs Controller General of India (DCGI), Prakash Kumar Singh, Director, Government and Regulatory Affairs, SII, said the vaccine Cervavac has demonstrated robust antibody response that is nearly 1,000 times higher than the baseline against all targetted HPV types, and in all dose and age groups.

The SII is also learnt to have made a presentation before the working group of HPV under the chairmanship of Dr NK Arora constituted separately by the National Technical Advisory Group on Immunization (NTAGI) to review the data and usefulness of this vaccine, the sources said.

In the application, Singh mentioned that every year, lakhs of women are diagnosed with cervical cancer as well as few other cancers and death ratio is also very high.

“Also, it is noteworthy that presently our country is fully dependent on foreign manufacturers for the HPV vaccine. In line with the philosophy of our group and under leadership of our CEO, Dr Adar C Poonawalla, it has always been our endeavour to make available high-quality ‘Made in India’ vaccines at affordable price for people of our country and world at large,” Singh said in the application.

“Like many other indigenous life-saving vaccines, we are committed to make our country Aatmanirbhar for India’s first indigenous life-saving qHPV vaccine also. This will fulfill the dream of our hon’ble Prime Minister Narendra Modi ‘Vocal for Local’ and ‘Making in India for the World’ and will ensure prevention of cancers caused by Human Papillomavirus (Type 6, 11, 16 & 18) vaccine recombinant,” Singh is learnt to have said in the application.

Edits by EP News Bureau